非诺贝特治疗与2型糖尿病患者CKD发病及进展的关联
中位随访4年,非诺贝特组eGFR下降更慢,微量白蛋白尿和大量白蛋白尿发生率更低,但CKD和肾衰竭发生率无差异。
要点
- 非诺贝特与安慰剂相比,eGFR年下降率更低(-0.28 vs -1.25 ml/min/1.73m²,P<0.01)。
- 非诺贝特降低微量白蛋白尿(HR 0.56,95%CI 0.43-0.72)和大量白蛋白尿(HR 0.72,95%CI 0.57-0.91)风险。
- 两组CKD发病率(HR 0.92,95%CI 0.74-1.15)和肾衰竭发病率(HR 0.95,95%CI 0.68-1.33)无显著差异。
核心结论
- 非诺贝特 randomization 与更低的白蛋白尿发生率和更慢的eGFR下降相关,但未降低CKD或肾衰竭发生率。
研究设计与样本
- ACCORD脂质试验的事后分析,纳入2636例非诺贝特组和2632例安慰剂组2型糖尿病患者,中位随访4年。
主要发现
- 非诺贝特组eGFR年下降率为-0.28 ml/min/1.73m²,安慰剂组为-1.25 ml/min/1.73m²(P<0.01)。
- 微量白蛋白尿发生率HR 0.56(95%CI 0.43-0.72,P<0.001),大量白蛋白尿HR 0.72(95%CI 0.57-0.91,P<0.001)。
- CKD发生率HR 0.92(95%CI 0.74-1.15,P=0.46),肾衰竭发生率HR 0.95(95%CI 0.68-1.33,P=0.76)。
临床怎么用
- 对于2型糖尿病患者,非诺贝特可能有助于减缓eGFR下降和减少白蛋白尿,但需关注其早期可逆性eGFR降低。
- 非诺贝特未显示降低CKD或肾衰竭风险,不应仅以肾脏保护为目的使用。
局限性
- 本研究为ACCORD试验的事后分析,结果需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Abnormalities in lipid metabolism may contribute to the development and progression of chronic kidney disease (CKD) in patients with type 2 diabetes. Fenofibrate induces early and reversible reduction in estimated glomerular filtration rate (eGFR), but it may have protective effects on microvascular complications of diabetes. We hypothesized that randomization to fenofibrate versus placebo would be associated with beneficial long-term effects on kidney outcomes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial participants. METHODS: We conducted a post hoc analysis in the ACCORD Lipid Trial to examine the association of randomization to fenofibrate versus placebo with change in eGFR and with time-to-development of microalbuminuria, macroalbuminuria, CKD, and kidney failure. RESULTS: We analyzed 2636 participants in the fenofibrate arm and 2632 in the placebo arm. During a median follow-up of 4 years, treatment with fenofibrate was associated with lower rate of eGFR decline (-0.28 ml/min per 1.73 m2 per year in the fenofibrate group vs. -1.25 ml/min per 1.73 m2 per year in the placebo group, P < 0.01) and with lower incidence of microalbuminuria (hazard ratio [HR] 0.56, 95% confidence interval [CI] 0.43-0.72, P < 0.001) and macroalbuminuria (HR 0.72, 95% CI 0.57-0.91, P < 0.001). There was no difference in incidence of CKD (HR 0.92, 95% CI 0.74-1.15, P = 0.46) and/or kidney failure (HR 0.95, 95% CI 0.68-1.33, P = 0.76). CONCLUSION: Compared with placebo, randomization to fenofibrate was associated with lower rates of incident albuminuria and a slower eGFR decline, but no difference in incidence of CKD or kidney failure in ACCORD participants.
引用
- Frazier R, Mehta R, Cai X, et al. Associations of Fenofibrate Therapy With Incidence and Progression of CKD in Patients With Type 2 Diabetes. Kidney Int Rep. 2018. PMID: 30596172. doi:10.1016/j.ekir.2018.09.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。